CIK 0001840425 · <br>Emerging growth company
OSR Health, Inc.
Sign in to watch- Tickers
- OSRH OSRHW
- Exchange
- OTC
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 845052822
- Phone
- 425-635-7700
- Business address
- 10900 NE 4TH STREET, SUITE 2300, BELLEVUE, WA, 98004
- Former names
- OSR Holdings, Inc., Bellevue Life Sciences Acquisition Corp.
Securities
- OSRH Common stock OTC
- OSRHW Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-14 | Bellevue Global Life Science Investors LLC 10% owner | Other acquisition | +43,000 | 2,043,500 | ||
| 2025-02-14 | Hwang Kuk Hyoun President and CEO | Other acquisition | +43,000 | 2,043,500 | ||
| 2025-02-14 | Hwang Kuk Hyoun President and CEO | Other acquisition | +7,531,634 | 9,575,134 | ||
| 2025-02-14 | Hwang Kuk Hyoun President and CEO | Other acquisition | +3,123,970 | 12,699,104 | ||
| 2023-03-23 | Hwang Kuk Hyoun Chief Executive Officer | Other disposition | −20,000 | 2,000,500 | ||
| 2023-03-23 | Hwang Kuk Hyoun Chief Executive Officer | Other disposition · Warrant for Common Stock | −20,000 | 370,000 | ||
| 2023-03-23 | Yoo David Jin Chief Financial Officer | Grant or award | +20,000 | 20,000 | ||
| 2023-03-23 | Yoo David Jin Chief Financial Officer | Grant or award · Warrant for Common Stock | +20,000 | 20,000 | ||
| 2023-03-23 | Bellevue Global Life Science Investors LLC 10% owner | Other disposition | −20,000 | 2,000,500 | ||
| 2023-03-23 | Bellevue Global Life Science Investors LLC 10% owner | Other disposition · Warrant for Common Stock | −20,000 | 370,000 | ||
| 2023-02-21 | Hwang Kuk Hyoun Chief Executive Officer | Other acquisition | +225,000 | 2,025,000 | ||
| 2023-02-21 | Hwang Kuk Hyoun Chief Executive Officer | Other disposition | −4,500 | 2,020,500 | ||
| 2023-02-21 | Bellevue Global Life Science Investors LLC 10% owner | Other acquisition | +225,000 | 2,025,000 | ||
| 2023-02-21 | Bellevue Global Life Science Investors LLC 10% owner | Other disposition | −4,500 | 2,020,500 | ||
| 2023-02-14 | REED STEVEN Director | Grant or award | +20,000 | 20,000 | ||
| 2023-02-14 | REED STEVEN Director | Grant or award · Warrant for Common Stock | +20,000 | 20,000 | ||
| 2023-02-14 | Chung In Chul Director | Grant or award | +20,000 | 20,000 | ||
| 2023-02-14 | Chung In Chul Director | Grant or award · Warrant for Common Stock | +20,000 | 20,000 | ||
| 2023-02-14 | Roberts Rad Director | Grant or award | +20,000 | 20,000 | ||
| 2023-02-14 | Park Jin Whan Director | Grant or award | +20,000 | 20,000 |
Page 1 of 3 · 43 trades